Werewolf Therapeutics Inc [HOWL] stock is trading at $1.49, down -1.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HOWL shares have gain 9.56% over the last week, with a monthly amount glided 7.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Werewolf Therapeutics Inc [NASDAQ: HOWL] stock has seen the most recent analyst activity on April 03, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $12. Previously, Wedbush started tracking the stock with Outperform rating on August 24, 2023, and set its price target to $9. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $26 on September 10, 2021. SVB Leerink initiated its recommendation with a Outperform and recommended $29 as its price target on May 25, 2021. Jefferies started tracking with a Buy rating for this stock on May 25, 2021, and assigned it a price target of $22. In a note dated May 25, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $32 on this stock.
Werewolf Therapeutics Inc [HOWL] stock has fluctuated between $1.26 and $8.19 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Werewolf Therapeutics Inc [NASDAQ: HOWL] shares were valued at $1.49 at the most recent close of the market. An investor can expect a potential return of 705.37% based on the average HOWL price forecast.
Analyzing the HOWL fundamentals
Werewolf Therapeutics Inc [NASDAQ:HOWL] reported sales of 3.39M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -19.55%, Pretax Profit Margin comes in at -18.35%, and Net Profit Margin reading is -18.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.59 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4400 points at the first support level, and at 1.3900 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5400, and for the 2nd resistance point, it is at 1.5900.
Ratios To Look Out For
For context, Werewolf Therapeutics Inc’s Current Ratio is 10.10. Also, the Quick Ratio is 10.10, while the Cash Ratio stands at 9.85. Considering the valuation of this stock, the price to sales ratio is 19.59, the price to book ratio is 0.73.
